Protein / target
Estrogen-related receptor gamma
Protein at a glance
Biological role
Sequence-specific double-stranded DNA binding
Strongest disease association
Movement Disorders
Therapeutic position
Clinically advancing target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Orphan receptor that acts as a transcription activator in the absence of bound ligand.
View complete UniProt function annotationHide complete annotation
Orphan receptor that acts as a transcription activator in the absence of bound ligand. Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements (By similarity). Induces the expression of PERM1 in the skeletal muscle
Subcellular location
Domains and Gene Ontology detail (20)Hide
Domains & features
Gene Ontology
- Cchromatin
- Cnucleoplasm
- Cnucleus
- FAF-2 domain binding
- FDNA-binding transcription activator activity, RNA polymerase II-specific
- FDNA-binding transcription factor activity, RNA polymerase II-specific
- Festrogen response element binding
- Fidentical protein binding
- Fnuclear receptor activity
- Fnuclear steroid receptor activity
- Fsequence-specific double-stranded DNA binding
- Fsteroid binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Nuclear receptor signalling
- ·nuclear receptor activity
Transcriptional regulation
- ·Orphan receptor that acts as a transcription activator in the absence of bound ligand. B…
- ·DNA-binding transcription activator activity, RNA polymerase II-specific
- ·DNA-binding transcription factor activity, RNA polymerase II-specific
- ·DNA-templated transcription
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Estrogen-related receptor gamma antagonist
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene ESRRG
Gene-level evidence surfaced through the gene ESRRGthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
1 compounds recorded · 1 in clinical development
View all recorded compounds (1)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Protein degraders — Emerging
View underlying tractability evidence (8)Hide
Raw Open Targets tractability assessment buckets, by modality.
Safety-related annotations
Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
ClinicalTrials.gov via the drug-target graph.